Behind the Scenes of Elysium Health

Elysium Health is a health company  that was founded in 2014. Dr. Leonard Guarente is the co-founder of the company. In addition to his responsibilities as chief scientist of Elysium Health, he serves as the director of the Paul F. Glenn Center for Biology of Aging Research at MIT. The company partners with scientists from prominent academic institutions such as the University of Oxford, Harvard University, and the University of Cambridge. The research of Elysium Health is spearheaded by the world-class scientists and clinicians on the company’s scientific advisory board. These scientists guide the direction of the company.

Elysium Health makes a daily supplement called Basis. This supplement is proven to increase  levels of NAD+ in our bodies. NAD+ is essential to hundreds of our cellular functions, including circadian rhythms, energy creation, and DNA health. As we age, our levels of NAD+ decline and those functions break down. By taking Basis, you can restore those levels back up and support your cellular well-being.

To ensure that Basis works as intended, Elysium Health put the supplement through a clinical trial. The trial divided 120 subjects into three groups. Group one took two capsules of Basis, which is the recommended daily dose of the supplement. Group two took four capsules of the supplement, which is double the recommended daily dose of Basis. Group three took a placebo. Those who took the recommended dose of Basis during the trial had their NAD+ levels increaseby an average of 40 percent and remain there for the duration of the trial. In order to ensure the most accurate results, the trial was double-blind and randomized.

Basis is sold through Elysium Health’s website. The company sells Basis in a variety of monthly subscriptions, as well as in individual jars. Each jar contains 60 capsules (the recommended daily intake is two capsules). A regular month-to-month subscription costs $50 each month. The most popular plan is the six-month subscription to Basis for $270, which breaks down to $45 per month. A one-year plan is $480, or $40 per month.

https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=318913187

Eric Lefkofsky Co-Founds Tempus To Further Cancer Treatment And Research

Lefkofsky was born in Southfield, Michigan with a simple background and had a childhood much like anyone else. After he graduated from the local high school, Eric went on to attend the University of Michigan and graduated in 1991. Eric Lefkofsky generated a large part of his fortune with his Groupon platform, which helped clients save money when it came to traveling and eating out at restaurants and such. As of late, he is the co-founder of a new company called Tempus along with his longtime friend Brad Keywell. Tempus will focus on genomic sequencing and is intended to greatly help with customizing treatments for cancer.

It made the headlines not too long ago that Eric Lefkosky had amazingly managed to raise a total of $70 million dollars in his latest round of funding for his company, Tempus. This funding, from several Lefkofsky associate investors, combined with previous funding, comes to a grand total of $130 million dollars. All together, that gives this new Chicago based company a net worth of nearly three-quarters of a billion dollars already.

As the CEO of Tempus, Lefkofsky is prepared to invest highly in his new business enterprise, with him and Keywell being the biggest investors so far. Just last year, Lefkofsky let it be known that he was ready to invest a large sum into Tempus to ensure its success, up to $100 million in capital.

Tempus is being created to allow for more precise treatments when it comes to cancer patients by bringing together the vast amounts of health-related data from around the world. Tempus has claimed it will build the largest database of data out there for healthcare for improving on cancer treatments. The company has so far partnered up with several other businesses as well to improve on their compilation of data. According to Lefkofsky, a large amount of the datasets available within healthcare are mostly disorganized and have insufficient data and now for the first time, there is technology available that will bring new possibilities.